News Image

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Provided By GlobeNewswire

Last update: Aug 14, 2025

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYTâ„¢ (cosibelimab-ipdl)

Read more at globenewswire.com

FORTRESS BIOTECH INC - FBIO 9 3/8 PERP

NASDAQ:FBIOP (8/15/2025, 8:18:30 PM)

7.88

+0.73 (+10.21%)


FORTRESS BIOTECH INC

NASDAQ:FBIO (8/15/2025, 8:18:30 PM)

After market: 2.17 +0.05 (+2.36%)

2.12

+0.16 (+8.16%)



Find more stocks in the Stock Screener

Follow ChartMill for more